Fuchs’ Endothelial Corneal Dystrophy: Genetics, Disease Mechanisms & Emerging Therapies

Scientific perspective for clinicians and readers interested in corneal research.

Updated October 3, 2026.

Fuchs’ endothelial corneal dystrophy (FECD) is a progressive disorder characterized by corneal endothelial cell loss, abnormal extracellular matrix deposition, and guttae formation. As endothelial function declines, impaired fluid regulation can lead to corneal edema and reduced visual quality.

Research increasingly connects these clinical findings with repeat-expansion genetics, abnormal RNA processing, cellular stress, and altered repair pathways. These discoveries are informing treatments that aim to support surviving cells, replace dysfunctional endothelium, or eventually modify the underlying disease process.

1. Genetics: A Major Driver, With Important Variability

TCF4 repeat expansion

An expansion of the CTG18.1 trinucleotide repeat within the TCF4 gene is a major genetic contributor to late-onset FECD. It is found in a large proportion of affected individuals of European ancestry, although its frequency varies across populations. It does not explain every case of FECD.[1]

Expanded repeat-containing RNA can accumulate within nuclei and disrupt RNA processing, including the activity of splicing regulators such as muscleblind-like proteins. Research also implicates changes in TCF4 transcript expression, indicating that more than one molecular mechanism may contribute to disease.[1]

Other genetic contributors

COL8A2 variants are associated with a rare early-onset form of FECD. Evidence also supports a role for certain SLC4A11 variants.

Other proposed genes require more cautious interpretation. A systematic review found that the evidence supporting ZEB1, LOXHD1, and AGBL1 as causes of FECD was less convincing or conflicting. A reported genetic association should therefore not automatically be interpreted as an established pathogenic mechanism.[2]

Why tissue-specific repeat instability matters?

Repeat length is not necessarily identical across tissues. Optical genome mapping has demonstrated substantial CTG18.1 repeat instability in affected corneal endothelial cells.[3]

This finding adds complexity to the relationship between a blood-based genetic measurement and the disease occurring within the cornea. Genetic results should be interpreted alongside the clinical phenotype rather than treated as a precise forecast of an individual patient’s progression.

2. Disease Mechanisms: Beyond Endothelial Cell Loss

Cellular stress and mitochondrial dysfunction

FECD involves abnormalities in cellular energy regulation and oxidative stress responses. Studies of affected endothelial cells and corneal tissue suggest that mitochondrial dysfunction contributes to the inability of surviving cells to maintain normal function.[15]

These findings provide a rationale for investigating treatments that preserve cellular health before extensive endothelial loss occurs.

TGF-β signaling and abnormal repair

Transforming growth factor beta (TGF-β) signaling is implicated in endothelial-to-mesenchymal transition, extracellular matrix changes, and altered endothelial migration.

Experimental work shows that increased migration does not necessarily represent healthy regeneration: cells may migrate while acquiring an abnormal, more fibrotic phenotype. Restoring a functional endothelial layer requires appropriate cell identity and organization, as well as movement across the posterior cornea.[4]

Hormonal biology

A cohort study of postmenopausal women found an association between current menopausal hormone therapy use and a modestly lower incidence of FECD. This observational finding does not establish causation or justify prescribing hormone therapy to prevent or treat FECD.[5]

Separately, experimental research has implicated estrogen metabolite–related DNA damage in models of endothelial injury.[6] These findings arise from different study settings and should not be combined into a simple claim that estrogen is uniformly protective or harmful.

3. Established Treatment: Endothelial Keratoplasty

For visually significant endothelial dysfunction, Descemet membrane endothelial keratoplasty (DMEK) and Descemet stripping automated endothelial keratoplasty (DSAEK), including ultrathin DSAEK, remain established surgical approaches.

These procedures replace dysfunctional endothelium with donor tissue. Randomized clinical trials have compared their visual and anatomical outcomes; procedure selection also depends on ocular anatomy, associated disease, and surgical considerations.[7]

Emerging therapies should be evaluated against these established treatments rather than assumed to offer equivalent outcomes for every patient.

4. Descemet Stripping Only: Using the Remaining Endothelium

Descemet stripping only (DSO), also called Descemetorhexis without endothelial keratoplasty (DWEK), removes a small central area of diseased Descemet membrane and endothelium without inserting a donor graft.

The approach depends on sufficient remaining peripheral endothelial capacity to repopulate the central area. It is therefore most relevant to carefully selected eyes with predominantly central disease.

What the clinical evidence shows

In the Sydney Eye Hospital study, 22 of 23 selected eyes treated with DSO and topical ripasudil achieved corneal clearance, with a mean clearance time of 4.1 weeks. This was a small pre–post study with historical comparisons, not a randomized trial.[8]

Long-term case-series evidence also supports sustained benefit in some eyes, while documenting that initial clearance does not guarantee permanent success.[9]

Patients should understand that recovery can be prolonged, edema may persist or recur, and subsequent endothelial keratoplasty may be necessary.

The role of ROCK inhibitors

Rho-associated protein kinase (ROCK) inhibitors are being investigated as adjuncts to endothelial repair. The DSO literature includes clinical experience with topical ripasudil, but results are specific to the drug, protocol, and selected population studied.[8]

ROCK inhibition should not be presented as a universally effective substitute for transplantation. Treatment requires attention to tolerability, monitoring, and local regulatory availability.

5. Cultured Corneal Endothelial Cell Therapy

Cultured endothelial cell therapy aims to restore endothelial function by injecting expanded donor-derived corneal endothelial cells into the anterior chamber, typically with a ROCK inhibitor.

Unlike endothelial keratoplasty, this approach delivers cells rather than a donor tissue sheet.

Clinical evidence

The original clinical study demonstrated the feasibility of cultured cell injection in patients with corneal endothelial failure. Its protocol included three hours of prone, face-down positioning after injection to encourage cell adhesion.[10] 

A subsequent 2025 study of 65 treated patients, with follow-up extending to ten years, reported encouraging long-term outcomes.[11] However, follow-up duration varied, the population included different causes of endothelial failure, and the study did not include a randomized keratoplasty comparison. It therefore does not establish superiority over DMEK or DSAEK.

What the guttae study actually demonstrated?

A 2024 FECD study evaluated surgical polishing of abnormal endothelial cells and extracellular material followed by cultured endothelial cell transplantation.[12]

The findings support a reduction in guttae through the combined procedure. They should not be interpreted as proof that injected cells alone dissolve existing guttae.

U.S. development status

On September 23, 2026, Aurion Biotech announced completion of enrollment in the U.S. ASTRA phase 3 trial of AURN001, an investigational combination of cultured allogeneic endothelial cells, neltependocel, and the ROCK inhibitor Y-27632.[13]

This is a development milestone reported by the manufacturer. It is not a published efficacy result or an announcement of U.S. regulatory approval.

6. Experimental Approaches Targeting Disease Biology

RNA-targeted therapies

Antisense oligonucleotides directed against the expanded TCF4 repeat have reduced RNA foci and corrected selected splicing abnormalities in experimental FECD systems.[14]

This provides proof of principle for targeting a disease-associated molecular mechanism. It does not yet establish a clinically effective treatment for patients.

Mitochondrial augmentation

Laboratory research has investigated whether introducing healthy mitochondria into affected endothelial cells can improve cellular function and reduce oxidative stress.[15]

The published findings are preclinical. They do not demonstrate improved vision, durable corneal clearance, or avoidance of transplantation in treated patients.

METTL3–m6A and TGF-β pathways

Research has implicated METTL3-mediated m6A RNA modification in TGF-β–associated endothelial-to-mesenchymal transition.[16]

These pathways may offer future therapeutic targets, but translating a laboratory effect into treatment requires evidence of effective delivery, sustained benefit, and ocular safety.

7. Clinical Perspective

FECD research now spans three complementary treatment goals:

The appropriate strategy depends on disease distribution, endothelial reserve, corneal clarity, associated ocular conditions, and the strength of evidence for the proposed treatment.

Scientific progress is expanding the possibilities. Careful patient selection and a clear distinction between established care and experimental therapy remain essential.

References